<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202393</url>
  </required_header>
  <id_info>
    <org_study_id>1370188-2</org_study_id>
    <secondary_id>R01MH122870</secondary_id>
    <nct_id>NCT04202393</nct_id>
  </id_info>
  <brief_title>Intervention for Comorbid Substance Use and Bipolar Disorders</brief_title>
  <acronym>ITAP</acronym>
  <official_title>RCT to Improve Post-Hospital Treatment Adherence for Comorbid Substance Use and Bipolar Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to evaluate the effectiveness of a novel intervention for patients with
      co-occurring bipolar and substance use disorders following a psychiatric hospitalization.
      Half of the participants will receive a specialized psychosocial intervention program, while
      the other half will receive an enhanced safety monitoring program, both provided in addition
      to their routine care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C)</measure>
    <time_frame>6 months</time_frame>
    <description>The Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C) assesses depressive symptom severity. Total scores range from 0 to 27 and higher scores indicated higher symptom severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician-Administered Rating Scale for Mania (CARS-M)</measure>
    <time_frame>6 months</time_frame>
    <description>The Clinician-Administered Rating Scale for Mania (CARS-M) assesses mania symptom severity. Total scores range from 0 to 50 and higher scores indicated higher symptom severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Integrated Treatment Adherence Program (ITAP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Assessment and Follow-up Evaluation (SAFE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Integrated Treatment Adherence Program (ITAP)</intervention_name>
    <description>Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.</description>
    <arm_group_label>Integrated Treatment Adherence Program (ITAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Safety Assessment and Follow-up Evaluation (SAFE)</intervention_name>
    <description>Enhanced assessment and evaluation with clinician feedback.</description>
    <arm_group_label>Safety Assessment and Follow-up Evaluation (SAFE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Diagnosis of a bipolar-spectrum disorder

          -  Diagnosis of a substance use disorder

          -  Taking at least one mood-stabilizing medication

        Exclusion:

          -  Unable to speak and read English

          -  Younger than age 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Gaudiano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Miller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Seon Park</last_name>
    <phone>401-680-4251</phone>
    <email>hspark@butler.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cheryl Cordeiro</last_name>
      <phone>401-455-6654</phone>
      <email>ccordeiro@butler.org</email>
    </contact>
    <investigator>
      <last_name>Brandon Gaudiano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Miller, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upload to NIMH Data Archive</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

